Showing 1894 results
April 2016
-
Story From Our Labs
Hooked on science, Jay Bradner becomes top researcher at Novartis
New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.
-
Press release
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
March 2016
-
Press release
Novartis publishes updated 2015 segment financials reflecting new division structure
Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY… -
In The News
CRISPR genome editing fuels cancer drug discovery
The better we know the molecular underpinnings of a disease, the better the odds of discovering new medicines for patients. CRISPR is changing the way medicines target cancer and other diseases. -
Story Patient Perspectives
Dealing with psoriasis
British actor and comedian Toby Hadoke talks about his struggles with psoriasis.
-
Story From Our Labs
When tiny brains are best for brain research
Zebrafish imaging sheds light on human neurological conditions.
-
Press release
Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
February 2016
-
Story From Our Labs
5 tips for making smart decisions on research projects
Make smart decisions about your research projects.
-
Press release
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as… -
In The News
Novartis Access perspectives: Tailoring tactics to tackle chronic disease in low-income countries
Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world -
Press release
Novartis shareholders approve all resolutions proposed by Board of Directors
Shareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as… -
Press release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration
Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions…